Abstract: Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Abstract: Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Abstract: Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner protein that is a non-thrombostasin protein. Further disclosed are vaccine compositions thrombostasin proteins having a comprising a carboxy terminal deletion, and methods for inhibiting a response to a thrombostasin protein in a host in need thereof, comprising the disclosed fusion proteins or vaccine compositions. Further disclosed are methods for the preparation of a fusion protein composition.

Abstract: Provided are methods and compositions for treating diarrhea, particularly secretory diarrhea, watery diarrhea and chemotherapy induced diarrhea (CID), in young and adult non-human companion animals, such as dogs and cats, with a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, in either enteric or non-enteric form.

Abstract: Methods of treating neonatal and young non-human animals suffering from diarrhea, and/or symptoms thereof, by administering to an animal in need thereof a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. are provided. In particular, the neonatal and young animals include calves, young equines and young camels, which frequently suffer from diarrhea of various etiologies, and the administered proanthocyanidin polymer composition is isolated from Croton lechleri. Further provided are methods of improving weight gain and/or reducing mortality in neonatal non-human animals by administration of the proanthocyanidin polymer composition. The composition, either enteric or non-enteric, can be in aqueous soluble form and orally administered to the affected neonatal and young animals. The invention also provides prebiotic compositions of botanical extracts of Croton spp. or of Calophyllum spp. useful to promote a beneficial intestinal microbiota.

Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: Methods of treating adult non-human animals afflicted with diarrhea, particularly, stress-induced diarrhea, by administering to an animal in need thereof an effective amount of a pharmaceutical formulation of a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. are provided. In particular, the adult animals include horses and camels which frequently suffer from stress-induced diarrhea and its symptoms, and the administered proanthocyanidin polymer composition is isolated from a Croton lechleri. The composition, which can be enteric or non-enteric, is administered particularly to target the intestine/gut of the animal via a mode and under conditions conducive and sufficient for providing effective treatment of diarrhea in the affected animal. Preferred modes of administration include orally providing an effective concentration of the proanthocyanidin polymer composition, e.g., via an oral paste formulation, drench, animal feed, or water bottle, to the affected animal.

Abstract: Methods of treating neonatal and young non-human animals suffering from diarrhea, and/or symptoms thereof, by administering to an animal in need thereof a proanthocyanidin polymer composition isolated from a Croton spp. or a Calophyllum spp. are provided. In particular, the neonatal and young animals include calves, young equines and young camels, which frequently suffer from diarrhea of various etiologies, and the administered proanthocyanidin polymer composition is isolated from Croton lechleri. Further provided are methods of improving weight gain and/or reducing mortality in neonatal non-human animals by administration of the proanthocyanidin polymer composition. The composition, either enteric or non-enteric, can be in aqueous soluble form and orally administered to the affected neonatal and young animals.

Abstract: Provided are methods of treating diarrhea, particularly malabsorption diarrhea, in neonatal, young and adult non-human animals, in which the diarrhea results from infection of the animals by Salmonella spp., such as Salmonella typhimurium, with a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, in either enteric or non-enteric form.

Abstract: Provided are methods and compositions for treating and preventing ulcers, ulceratic conditions and/or the symptoms thereof, including gastric, intestinal, e.g., duodenal, and colonic ulcers in non-human animals, especially horses. The methods involve treating an afflicted animal a compositions comprising effective amounts of one or more acid reducing or inhibiting drugs, such as antacids and/or a proton-ion pump inhibitors, and a therapeutically effective amount of a proanthocyanidin polymer from Croton lechleri, or a Croton lechleri extract, in either enteric or non-enteric form. The ulcer treatment compositions are formulated as a paste, gel, or gel paste containing associated microparticles comprising antacid, proton-ion inhibitor, and C. lechleri proanthocyanidin polymer or C. lechleri extract, as well as other components, to particularly provide a colon targeted delivery system to treat and prevent ulcers in animals in need.

Abstract: A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent.

Abstract: A sustained release apparatus including at least one sustained release mini-implant or pellet; the or each mini-implant or pellet including: a sustained release support material; and a pharmaceutical composition including a Luteinising Hormone Releasing Hormone (HLRH) agonist and/or antagonist component the size and/or number and/or payload of mini-implant(s) or pellet(s) providing, release of LHRH agonist and/or antagonist at, or above, a desired threshold level for treatment of a selected indication, the apparatus providing approximately zero order release of the LHRH agonist and/or antagonist.

Abstract: A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one growth and/or reproduction-associated pharmaceutical component; analogue thereof or derivative thereof; and a carrier therefor.

Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.

Abstract: A sustained release mini-implant including a silicone support material; and a pharmaceutically active composition carried in or on the silicone support rod; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally a carrier therefor; the mini-implant providing a predetermined threshold blood level of pharmaceutical active for treatment of a selected indication.

Abstract: The subject invention provides a fusion protein for producing a dual immune response in a vertebrate, which fusion protein comprises: (a) a first proteinaceous portion analogous to all or part of a peptide endogenously synthesized within the vertebrate, the activity of which peptide is to be inhibited within the vertebrate, and which proteinaceous portion by itself is incapable of eliciting an effective immunoinhibitory response in said vertebrate; connected to (b) a second proteinaceous portion analogous to all or part of an immunogen from a pathogen, which pathogen is capable of pathogenically infecting the vertebrate; the portion (b) causing the vertebrate's immune system to recognize the portion (a) and produce a response that: (i) inhibits the activity of the peptide endogenously synthesized within the vertebrate; and (ii) protects the vertebrate from infection by the pathogen, when the vertebrate is vaccinated with an effective amount of the fusion protein.

Abstract: An at least partially radio-opaque sustained release delivery apparatus including a sustained release support material; a pharmaceutically active composition carried in or on the sustained release support material; and a material which renders the delivery apparatus at least partially radio-opaque; the pharmaceutically active composition including at least one pharmaceutically active component; and optionally carrier therefor; the pharmaceutically active component being present in amounts of from approximately 30% to 75% by weight, based on the total weight of the sustained release delivery apparatus; the radio-opaque material being carried in the support material, and/or in the pharmaceutically active composition.

Abstract: A sustained release delivery apparatus including a silicone support material formed from a methyl-vinyl siloxane polymer including a fumed silica as a reinforcing filler; a pharmaceutically active composition carried in or on the silicone support material; the pharmaceutically active composition including at least one growth and/or reproduction-associated pharmaceutical component; analogue thereof or derivative thereof; and a carrier therefor.